What is the current consensus among gynecologists about the heart risks of starting bioidentical hormone replacement therapy after age sixty?
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
What is the current consensus among gynecologists about the heart risks of starting bioidentical hormone replacement therapy after age sixty?
3 real searches · 1 real-search pass
2026 menopause hormone therapy starting after age 60 cardiovascular risk guideline NAMS ACOG Endocrine SocietyGoogle ↗
OBSERVED
FDA approved bioidentical estradiol progesterone compounded bioidentical hormones cardiovascular safety ACOGGoogle ↗
OBSERVED
AHA menopause hormone therapy cardiovascular disease timing hypothesis older than 60 risks stroke venous thromboembolismGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 3 queries…
Searches and sources
ChatGPT3 real searches · gpt-6
2026 menopause hormone therapy starting after age 60 cardiovascular risk guideline NAMS ACOG Endocrine Society Google ↗
FDA approved bioidentical estradiol progesterone compounded bioidentical hormones cardiovascular safety ACOG Google ↗
AHA menopause hormone therapy cardiovascular disease timing hypothesis older than 60 risks stroke venous thromboembolism Google ↗
- The 2022 hormone therapy position statement of The North American Menopause Society · pubmed.ncbi.nlm.nih.gov
- The 2022 hormone therapy position statement of... : Menopause · doi.org
- Compounded Bioidentical Menopausal Hormone Therapy · acog.org
- Menopause · fda.gov
- ACOG Clinical Practice Guideline: Management of... : Obstetrics & Gynecology · doi.org
- New 2026 American College of Obstetricians and Gynecologists Menopause Symptoms Guideline – Key Recommendations · guidelinecentral.com
- Menopause Hormone Therapy in Women With Cardiovascular Risk Factors or Established Ischemic Heart Disease: A Joint FIGO and WHF Position Paper · pmc.ncbi.nlm.nih.gov
Queries
3 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
2026 menopause hormone therapy starting after age 60 cardiovascular risk guideline NAMS ACOG Endocrine Society OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
FDA approved bioidentical estradiol progesterone compounded bioidentical hormones cardiovascular safety ACOG OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
AHA menopause hormone therapy cardiovascular disease timing hypothesis older than 60 risks stroke venous thromboembolism OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |